Connection

HASHEM EL-SERAG to Adenocarcinoma

This is a "connection" page, showing publications HASHEM EL-SERAG has written about Adenocarcinoma.
Connection Strength

8.088
  1. Why Has Screening and Surveillance for Barrett's Esophagus Fallen Short in Stemming the Rising Incidence of Esophageal Adenocarcinoma? Am J Gastroenterol. 2023 04 01; 118(4):590-592.
    View in: PubMed
    Score: 0.489
  2. Current Status of Chemoprevention in Barrett's Esophagus. Gastrointest Endosc Clin N Am. 2021 Jan; 31(1):117-130.
    View in: PubMed
    Score: 0.421
  3. External Validation of the Michigan Barrett's Esophagus Prediction Tool. Clin Gastroenterol Hepatol. 2017 07; 15(7):1124-1126.
    View in: PubMed
    Score: 0.327
  4. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus. Am J Gastroenterol. 2017 Jul; 112(7):1049-1055.
    View in: PubMed
    Score: 0.327
  5. Sex and Racial Disparity in Incidence of Esophageal Adenocarcinoma: Observations and Explanations. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):330-2.
    View in: PubMed
    Score: 0.298
  6. Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett's oesophagus. Gut. 2016 08; 65(8):1252-60.
    View in: PubMed
    Score: 0.294
  7. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study. Gastroenterology. 2015 Nov; 149(6):1392-8.
    View in: PubMed
    Score: 0.292
  8. Esophageal carcinoma. N Engl J Med. 2015 04 09; 372(15):1472-3.
    View in: PubMed
    Score: 0.286
  9. Esophageal carcinoma. N Engl J Med. 2014 Dec 25; 371(26):2499-509.
    View in: PubMed
    Score: 0.281
  10. The incidence of esophageal adenocarcinoma in a national veterans cohort with Barrett's esophagus. Am J Gastroenterol. 2014 Dec; 109(12):1862-8; quiz 1861, 1869.
    View in: PubMed
    Score: 0.277
  11. Risk of upper gastrointestinal cancers in patients with gastroesophageal reflux disease after a negative screening endoscopy. Clin Gastroenterol Hepatol. 2015 Feb; 13(2):280-6.
    View in: PubMed
    Score: 0.272
  12. Decision aids for shared decision-making in Barrett's esophagus surveillance. Clin Gastroenterol Hepatol. 2015 Jan; 13(1):91-3.
    View in: PubMed
    Score: 0.269
  13. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut. 2014 Aug; 63(8):1229-37.
    View in: PubMed
    Score: 0.260
  14. Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Dig Dis Sci. 2010 Dec; 55(12):3404-7.
    View in: PubMed
    Score: 0.203
  15. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology. 2010 Jun; 138(7):2260-6.
    View in: PubMed
    Score: 0.201
  16. Alcohol drinking and the risk of Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology. 2009 Apr; 136(4):1155-7.
    View in: PubMed
    Score: 0.187
  17. Phase I and II enzyme polymorphisms as risk factors for Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis. Dis Esophagus. 2009; 22(7):571-87.
    View in: PubMed
    Score: 0.187
  18. Secular trends in the use, quality, and outcomes of gastrectomy for noncardia gastric cancer in the United States. Ann Surg Oncol. 2007 Sep; 14(9):2519-27.
    View in: PubMed
    Score: 0.167
  19. Noncardia gastric adenocarcinoma remains an important and deadly cancer in the United States: secular trends in incidence and survival. Am J Gastroenterol. 2006 Nov; 101(11):2485-92.
    View in: PubMed
    Score: 0.159
  20. The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther. 2006 Jul 01; 24(1):87-94.
    View in: PubMed
    Score: 0.156
  21. Emergency Presentations Predict Worse Outcomes Among Patients with Pancreatic Cancer. Dig Dis Sci. 2024 Feb; 69(2):603-614.
    View in: PubMed
    Score: 0.131
  22. The Impact of Race on Pancreatic Cancer Treatment and Survival in the Nationwide Veterans Affairs Healthcare System. Pancreas. 2024 Jan 01; 53(1):e27-e33.
    View in: PubMed
    Score: 0.130
  23. Diabetes Status and Pancreatic Cancer Survival in the Nationwide Veterans Affairs Healthcare System. Dig Dis Sci. 2023 09; 68(9):3634-3643.
    View in: PubMed
    Score: 0.127
  24. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol. 2003 Jul; 98(7):1627-33.
    View in: PubMed
    Score: 0.127
  25. Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy. J Gastroenterol. 2022 12; 57(12):942-951.
    View in: PubMed
    Score: 0.121
  26. Missed Opportunities for Screening or Surveillance Among Patients with Newly Diagnosed Non-cardia Gastric Adenocarcinoma. Dig Dis Sci. 2023 03; 68(3):761-769.
    View in: PubMed
    Score: 0.118
  27. The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am. 2002 Jun; 31(2):421-40, viii.
    View in: PubMed
    Score: 0.118
  28. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut. 2002 Mar; 50(3):368-72.
    View in: PubMed
    Score: 0.115
  29. External validation of a model determining risk of neoplastic progression of Barrett's esophagus in a cohort of U.S. veterans. Gastrointest Endosc. 2022 06; 95(6):1113-1122.
    View in: PubMed
    Score: 0.114
  30. Prevalence and Predictors of Missed Dysplasia on Index Barrett's Esophagus Diagnosing Endoscopy in a Veteran Population. Clin Gastroenterol Hepatol. 2022 04; 20(4):e876-e889.
    View in: PubMed
    Score: 0.109
  31. Segment length and risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med. 2000 Nov 07; 133(9):747-8.
    View in: PubMed
    Score: 0.105
  32. Systematic review with meta-analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients. Aliment Pharmacol Ther. 2020 07; 52(1):20-36.
    View in: PubMed
    Score: 0.102
  33. Prevalence of Helicobacter pylori Positive Non-cardia Gastric Adenocarcinoma Is Low and Decreasing in a US Population. Dig Dis Sci. 2020 08; 65(8):2403-2411.
    View in: PubMed
    Score: 0.098
  34. Missed Opportunities for Screening and Surveillance of Barrett's Esophagus in Veterans with Esophageal Adenocarcinoma. Dig Dis Sci. 2019 02; 64(2):367-372.
    View in: PubMed
    Score: 0.092
  35. Prior Diagnosis of Barrett's Esophagus Is Infrequent, but Associated with Improved Esophageal Adenocarcinoma Survival. Dig Dis Sci. 2018 11; 63(11):3112-3119.
    View in: PubMed
    Score: 0.090
  36. Underuse of Surgery Accounts for Racial Disparities in Esophageal Cancer Survival Times: A Matched Cohort Study. Clin Gastroenterol Hepatol. 2019 03; 17(4):657-665.e13.
    View in: PubMed
    Score: 0.090
  37. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans. Aliment Pharmacol Ther. 2018 08; 48(4):469-477.
    View in: PubMed
    Score: 0.090
  38. The Association Between Statin Use After Diagnosis and Mortality Risk in Patients With Esophageal Cancer: A Retrospective Cohort Study of United States Veterans. Am J Gastroenterol. 2018 09; 113(9):1310.
    View in: PubMed
    Score: 0.089
  39. Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Am J Gastroenterol. 2018 08; 113(8):1148-1155.
    View in: PubMed
    Score: 0.089
  40. Risk of oesophageal adenocarcinoma in individuals with Barrett's oesophagus. Eur J Cancer. 2017 04; 75:41-46.
    View in: PubMed
    Score: 0.081
  41. Opportunities for Preventing Esophageal Adenocarcinoma. Cancer Prev Res (Phila). 2016 Nov; 9(11):828-834.
    View in: PubMed
    Score: 0.079
  42. Esophageal adenocarcinoma after obesity surgery in a population-based cohort study. Surg Obes Relat Dis. 2017 Jan; 13(1):28-34.
    View in: PubMed
    Score: 0.074
  43. Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology. 2015 Nov; 149(6):1599-606.
    View in: PubMed
    Score: 0.073
  44. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013 Nov; 11(11):1399-1412.e7.
    View in: PubMed
    Score: 0.063
  45. Incidence and survival of colorectal cancer among Hispanics in the United States: a population-based study. Dig Dis Sci. 2013 Jul; 58(7):2052-60.
    View in: PubMed
    Score: 0.060
  46. Surveillance in Barrett's esophagus: lessons from behavioral economics. Gastroenterology. 2009 Sep; 137(3):763-5.
    View in: PubMed
    Score: 0.048
  47. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008 Mar; 67(3):394-8.
    View in: PubMed
    Score: 0.043
  48. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005 Aug 02; 143(3):199-211.
    View in: PubMed
    Score: 0.037
  49. Barrett's esophagus, hiatal hernia, and logistic regression analysis. Am J Gastroenterol. 1999 Dec; 94(12):3395-6.
    View in: PubMed
    Score: 0.025
  50. Opposing time trends of peptic ulcer and reflux disease. Gut. 1998 Sep; 43(3):327-33.
    View in: PubMed
    Score: 0.023
  51. Menopausal hormone therapy and the risk of esophageal and gastric cancer. Int J Cancer. 2017 04 01; 140(7):1693-1699.
    View in: PubMed
    Score: 0.020
  52. Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus. Am J Gastroenterol. 2016 11; 111(11):1528-1535.
    View in: PubMed
    Score: 0.020
  53. Weight Change and Weight Cycling Are?Not?Associated With Risk of Barrett's?Esophagus. Clin Gastroenterol Hepatol. 2016 12; 14(12):1839-1840.
    View in: PubMed
    Score: 0.019
  54. Patients' intuitive judgments about surveillance endoscopy in Barrett's esophagus: a review and application to models of decision-making. Dis Esophagus. 2013 Sep-Oct; 26(7):682-9.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.